Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00605254 · ClinicalTrials.gov registry record

PET Imaging of P-glycoprotein Function Using [11C]dLop

A clinical trial, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
58
Enrollment target

NCT00605254: Completed study, sponsored by National Institute of Mental Health (NIMH).

NCT00605254 is a clinical trial that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00605254 has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
58 participants
Enrollment target

Study Summary

This study will test the use of a radioactive substance called \[11C\]dLop for measuring P-glycoprotein (P-gp) using positron emission tomography (PET) imaging. The P-gp protein acts as a pump in cells, affecting a variety of functions, such as limiting drug absorption and elimination and decreasing drug penetration into certain tissues, such as the brain. It is a major obstacle to successful chemotherapy because it can pump cancer drugs out of the cells, interfering with treatment. Decreased P-gp function may contribute to disorders such as Parkinson s disease and Alzheimer s disease, whereas higher levels of the protein have been found in patients with epilepsy and in several forms of drug-resistant cancer tumors. This study will determine uptake and clearance of \[11C\]dLop and the radiation exposure to organs of the body to assess its possible use in further studies of P-gp function. Healthy normal volunteers between 18 and 51 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination and blood and urine tests. Participants undergo the following procedures: * Electrocardiogram (ECG): A test of the electrical function of the heart. * Brain PET scans: PET imaging uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is \[18F\]FMPEP-d(2). Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. A brief scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans.

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2008-01-24
Est. Completion 2014-09-04

What the finished NCT00605254 record still lists

NCT00605254 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT00605254 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00605254 about?

NCT00605254 is a clinical study titled "PET Imaging of P-glycoprotein Function Using [11C]dLop". This study will test the use of a radioactive substance called \[11C\]dLop for measuring P-glycoprotein (P-gp) using positron emission tomography (PET) imaging. The P-gp protein acts as a pump in cells, affecting a variety of functions, such as limiting drug absorption and elimination and decreasing...

What is the current status of trial NCT00605254?

This trial is currently completed. The enrollment target is 58 participants. The study started on 2008-01-24. Estimated completion is 2014-09-04.

Who is sponsoring clinical trial NCT00605254?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00605254, the US trial registry maintained by the National Library of Medicine. NCT00605254 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.